These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 33177491

  • 1. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene.
    Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X, Zhang M, Chen X, Pan T, Yan L, Jin T, Wang J, Lv Q, Sui X, Xie T.
    Cell Death Dis; 2020 Nov 11; 11(11):969. PubMed ID: 33177491
    [Abstract] [Full Text] [Related]

  • 2. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2019 Dec 09; 12(1):135. PubMed ID: 31818312
    [Abstract] [Full Text] [Related]

  • 3. Phenethyl isothiocyanate synergistically induces apoptosis with Gefitinib in non-small cell lung cancer cells via endoplasmic reticulum stress-mediated degradation of Mcl-1.
    Zhang Q, Chen M, Cao L, Ren Y, Guo X, Wu X, Xu K.
    Mol Carcinog; 2020 Jun 09; 59(6):590-603. PubMed ID: 32189414
    [Abstract] [Full Text] [Related]

  • 4. Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF.
    Song X, Wang L, Cai P, Xu Y, Liu Q, Fan D.
    Toxicol Appl Pharmacol; 2024 May 09; 486():116938. PubMed ID: 38642809
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.
    Pan C, Duan H, Wu Y, Zhu C, Yi C, Duan Y, Lu D, Guo C, Wu D, Wang Y, Fu X, Xu J, Chen Y, Luo M, Tian W, Pan T, Xu W, Zhang S, Huang J.
    Int J Oncol; 2020 Oct 09; 57(4):939-955. PubMed ID: 32945394
    [Abstract] [Full Text] [Related]

  • 6. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, Shi R, Liu M, Liu C, Chen C, Liu H, Chen J.
    BMC Cancer; 2020 Dec 04; 20(1):1189. PubMed ID: 33276757
    [Abstract] [Full Text] [Related]

  • 7. Mechanistic insights into Yifei Sanjie pill's regulation of EMT to enhance gefitinib treatment effect in NSCLC by in silico analysis and experimental validation.
    Zhou R, Qin B, Zhuang Z, Li J, Shi Y, Gao T, Wu D, Yuan Y, Tang Y, Lin L.
    J Ethnopharmacol; 2024 Nov 15; 334():118343. PubMed ID: 38750985
    [Abstract] [Full Text] [Related]

  • 8. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C, Gao W, Liu J, Cheng H, Hao J.
    Respir Res; 2020 Aug 10; 21(1):210. PubMed ID: 32778129
    [Abstract] [Full Text] [Related]

  • 9. Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
    Bokobza SM, Jiang Y, Weber AM, Devery AM, Ryan AJ.
    Oncotarget; 2014 Jul 15; 5(13):4765-78. PubMed ID: 24946858
    [Abstract] [Full Text] [Related]

  • 10. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
    Ma C, Zhang X, Mo X, Yu Y, Xiao Z, Wu J, Ding L, Lei C, Zhu Y, Zhang H.
    Phytomedicine; 2024 Mar 15; 125():155351. PubMed ID: 38232540
    [Abstract] [Full Text] [Related]

  • 11. Enhancing the Therapeutic Efficacy of Gefitinib in Human Non-Small-Cell Lung Cancer through Drug Combination.
    Zhang M, Cai H, Du Y, Wang Y, Gong J, Xu J, Liu X.
    Mol Pharm; 2021 Mar 01; 18(3):1397-1407. PubMed ID: 33471533
    [Abstract] [Full Text] [Related]

  • 12. MiRNA-153-3p promotes gefitinib-sensitivity in non-small cell lung cancer by inhibiting ATG5 expression and autophagy.
    Zhang W, Dong YZ, Du X, Peng XN, Shen QM.
    Eur Rev Med Pharmacol Sci; 2019 Mar 01; 23(6):2444-2452. PubMed ID: 30964170
    [Abstract] [Full Text] [Related]

  • 13. β-Elemene Reverses Gefitinib Resistance in NSCLC Cells by Inhibiting lncRNA H19-Mediated Autophagy.
    Zhang R, Zheng Y, Zhu Q, Gu X, Xiang B, Gu X, Xie T, Sui X.
    Pharmaceuticals (Basel); 2024 May 14; 17(5):. PubMed ID: 38794196
    [Abstract] [Full Text] [Related]

  • 14. Combined treatment with N-acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line.
    Li J, Wang XH, Hu J, Shi M, Zhang L, Chen H.
    Cancer Med; 2020 Feb 14; 9(4):1495-1502. PubMed ID: 31891230
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid re‑sensitises gefitinib‑resistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelial‑mesenchymal transition.
    Yang X, Gao Y, Liu Q, Wan L, Liu H, Bian W, Du Y, Huang C.
    Oncol Rep; 2021 Feb 14; 45(2):459-468. PubMed ID: 33416163
    [Abstract] [Full Text] [Related]

  • 16. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K, Wang L, Wei A, Jia X, Liu X.
    Thorac Cancer; 2020 Jun 14; 11(6):1566-1577. PubMed ID: 32368855
    [Abstract] [Full Text] [Related]

  • 17. Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase.
    Cao L, Hong W, Cai P, Xu C, Bai X, Zhao Z, Huang M, Jin J.
    Eur J Pharmacol; 2021 Jan 05; 890():173647. PubMed ID: 33049304
    [Abstract] [Full Text] [Related]

  • 18. Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells.
    Yang J, Wu W, Wen J, Ye H, Luo H, Bai P, Tang M, Wang F, Zheng L, Yang S, Li W, Peng A, Yang L, Wan L, Chen L.
    Biomaterials; 2017 Oct 05; 141():188-198. PubMed ID: 28689115
    [Abstract] [Full Text] [Related]

  • 19. RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy.
    Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G.
    EMBO J; 2020 Jun 17; 39(12):e103181. PubMed ID: 32368828
    [Abstract] [Full Text] [Related]

  • 20. Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells.
    Tong CWS, Wu MMX, Yan VW, Cho WCS, To KKW.
    Cancer Treat Res Commun; 2020 Jun 17; 25():100229. PubMed ID: 33152554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.